1 Introduction to Research & Analysis Reports
1.1 Parkinsons Disease Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Parkinsons Disease Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Parkinsons Disease Drug Overall Market Size
2.1 Global Parkinsons Disease Drug Market Size: 2022 VS 2029
2.2 Global Parkinsons Disease Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Parkinsons Disease Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Parkinsons Disease Drug Players in Global Market
3.2 Top Global Parkinsons Disease Drug Companies Ranked by Revenue
3.3 Global Parkinsons Disease Drug Revenue by Companies
3.4 Global Parkinsons Disease Drug Sales by Companies
3.5 Global Parkinsons Disease Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Parkinsons Disease Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Parkinsons Disease Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Parkinsons Disease Drug Players in Global Market
3.8.1 List of Global Tier 1 Parkinsons Disease Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Parkinsons Disease Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Parkinsons Disease Drug Market Size Markets, 2022 & 2029
4.1.2 Carbidopa/Levodopa
4.1.3 Dopamine Receptor Agonists
4.1.4 MAO-Inhibitors
4.2 By Type – Global Parkinsons Disease Drug Revenue & Forecasts
4.2.1 By Type – Global Parkinsons Disease Drug Revenue, 2018-2023
4.2.2 By Type – Global Parkinsons Disease Drug Revenue, 2024-2029
4.2.3 By Type – Global Parkinsons Disease Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Parkinsons Disease Drug Sales & Forecasts
4.3.1 By Type – Global Parkinsons Disease Drug Sales, 2018-2023
4.3.2 By Type – Global Parkinsons Disease Drug Sales, 2024-2029
4.3.3 By Type – Global Parkinsons Disease Drug Sales Market Share, 2018-2029
4.4 By Type – Global Parkinsons Disease Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Parkinsons Disease Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinics
5.1.4 Other
5.2 By Application – Global Parkinsons Disease Drug Revenue & Forecasts
5.2.1 By Application – Global Parkinsons Disease Drug Revenue, 2018-2023
5.2.2 By Application – Global Parkinsons Disease Drug Revenue, 2024-2029
5.2.3 By Application – Global Parkinsons Disease Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Parkinsons Disease Drug Sales & Forecasts
5.3.1 By Application – Global Parkinsons Disease Drug Sales, 2018-2023
5.3.2 By Application – Global Parkinsons Disease Drug Sales, 2024-2029
5.3.3 By Application – Global Parkinsons Disease Drug Sales Market Share, 2018-2029
5.4 By Application – Global Parkinsons Disease Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Parkinsons Disease Drug Market Size, 2022 & 2029
6.2 By Region – Global Parkinsons Disease Drug Revenue & Forecasts
6.2.1 By Region – Global Parkinsons Disease Drug Revenue, 2018-2023
6.2.2 By Region – Global Parkinsons Disease Drug Revenue, 2024-2029
6.2.3 By Region – Global Parkinsons Disease Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Parkinsons Disease Drug Sales & Forecasts
6.3.1 By Region – Global Parkinsons Disease Drug Sales, 2018-2023
6.3.2 By Region – Global Parkinsons Disease Drug Sales, 2024-2029
6.3.3 By Region – Global Parkinsons Disease Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Parkinsons Disease Drug Revenue, 2018-2029
6.4.2 By Country – North America Parkinsons Disease Drug Sales, 2018-2029
6.4.3 US Parkinsons Disease Drug Market Size, 2018-2029
6.4.4 Canada Parkinsons Disease Drug Market Size, 2018-2029
6.4.5 Mexico Parkinsons Disease Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Parkinsons Disease Drug Revenue, 2018-2029
6.5.2 By Country – Europe Parkinsons Disease Drug Sales, 2018-2029
6.5.3 Germany Parkinsons Disease Drug Market Size, 2018-2029
6.5.4 France Parkinsons Disease Drug Market Size, 2018-2029
6.5.5 U.K. Parkinsons Disease Drug Market Size, 2018-2029
6.5.6 Italy Parkinsons Disease Drug Market Size, 2018-2029
6.5.7 Russia Parkinsons Disease Drug Market Size, 2018-2029
6.5.8 Nordic Countries Parkinsons Disease Drug Market Size, 2018-2029
6.5.9 Benelux Parkinsons Disease Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Parkinsons Disease Drug Revenue, 2018-2029
6.6.2 By Region – Asia Parkinsons Disease Drug Sales, 2018-2029
6.6.3 China Parkinsons Disease Drug Market Size, 2018-2029
6.6.4 Japan Parkinsons Disease Drug Market Size, 2018-2029
6.6.5 South Korea Parkinsons Disease Drug Market Size, 2018-2029
6.6.6 Southeast Asia Parkinsons Disease Drug Market Size, 2018-2029
6.6.7 India Parkinsons Disease Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Parkinsons Disease Drug Revenue, 2018-2029
6.7.2 By Country – South America Parkinsons Disease Drug Sales, 2018-2029
6.7.3 Brazil Parkinsons Disease Drug Market Size, 2018-2029
6.7.4 Argentina Parkinsons Disease Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Parkinsons Disease Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Parkinsons Disease Drug Sales, 2018-2029
6.8.3 Turkey Parkinsons Disease Drug Market Size, 2018-2029
6.8.4 Israel Parkinsons Disease Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Parkinsons Disease Drug Market Size, 2018-2029
6.8.6 UAE Parkinsons Disease Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Teva
7.1.1 Teva Company Summary
7.1.2 Teva Business Overview
7.1.3 Teva Parkinsons Disease Drug Major Product Offerings
7.1.4 Teva Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.1.5 Teva Key News & Latest Developments
7.2 Novartis AG
7.2.1 Novartis AG Company Summary
7.2.2 Novartis AG Business Overview
7.2.3 Novartis AG Parkinsons Disease Drug Major Product Offerings
7.2.4 Novartis AG Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.2.5 Novartis AG Key News & Latest Developments
7.3 GSK
7.3.1 GSK Company Summary
7.3.2 GSK Business Overview
7.3.3 GSK Parkinsons Disease Drug Major Product Offerings
7.3.4 GSK Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.3.5 GSK Key News & Latest Developments
7.4 AbbVie
7.4.1 AbbVie Company Summary
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Parkinsons Disease Drug Major Product Offerings
7.4.4 AbbVie Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.4.5 AbbVie Key News & Latest Developments
7.5 Merck
7.5.1 Merck Company Summary
7.5.2 Merck Business Overview
7.5.3 Merck Parkinsons Disease Drug Major Product Offerings
7.5.4 Merck Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.5.5 Merck Key News & Latest Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Summary
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Parkinsons Disease Drug Major Product Offerings
7.6.4 Boehringer Ingelheim Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.6.5 Boehringer Ingelheim Key News & Latest Developments
7.7 Impax Laboratories
7.7.1 Impax Laboratories Company Summary
7.7.2 Impax Laboratories Business Overview
7.7.3 Impax Laboratories Parkinsons Disease Drug Major Product Offerings
7.7.4 Impax Laboratories Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.7.5 Impax Laboratories Key News & Latest Developments
7.8 Lundbeck
7.8.1 Lundbeck Company Summary
7.8.2 Lundbeck Business Overview
7.8.3 Lundbeck Parkinsons Disease Drug Major Product Offerings
7.8.4 Lundbeck Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.8.5 Lundbeck Key News & Latest Developments
7.9 Sun Pharma
7.9.1 Sun Pharma Company Summary
7.9.2 Sun Pharma Business Overview
7.9.3 Sun Pharma Parkinsons Disease Drug Major Product Offerings
7.9.4 Sun Pharma Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.9.5 Sun Pharma Key News & Latest Developments
7.10 Wockhardt
7.10.1 Wockhardt Company Summary
7.10.2 Wockhardt Business Overview
7.10.3 Wockhardt Parkinsons Disease Drug Major Product Offerings
7.10.4 Wockhardt Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.10.5 Wockhardt Key News & Latest Developments
7.11 UCB
7.11.1 UCB Company Summary
7.11.2 UCB Parkinsons Disease Drug Business Overview
7.11.3 UCB Parkinsons Disease Drug Major Product Offerings
7.11.4 UCB Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.11.5 UCB Key News & Latest Developments
7.12 Bausch Health
7.12.1 Bausch Health Company Summary
7.12.2 Bausch Health Parkinsons Disease Drug Business Overview
7.12.3 Bausch Health Parkinsons Disease Drug Major Product Offerings
7.12.4 Bausch Health Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.12.5 Bausch Health Key News & Latest Developments
7.13 Acadia
7.13.1 Acadia Company Summary
7.13.2 Acadia Parkinsons Disease Drug Business Overview
7.13.3 Acadia Parkinsons Disease Drug Major Product Offerings
7.13.4 Acadia Parkinsons Disease Drug Sales and Revenue in Global (2018-2023)
7.13.5 Acadia Key News & Latest Developments
8 Global Parkinsons Disease Drug Production Capacity, Analysis
8.1 Global Parkinsons Disease Drug Production Capacity, 2018-2029
8.2 Parkinsons Disease Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Parkinsons Disease Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Parkinsons Disease Drug Supply Chain Analysis
10.1 Parkinsons Disease Drug Industry Value Chain
10.2 Parkinsons Disease Drug Upstream Market
10.3 Parkinsons Disease Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Parkinsons Disease Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界のパーキンソン病用薬剤市場予測2023-2029：カルビドパ/レボドパ、ドーパミン受容体作動薬、MAO阻害剤 |
| 【英語タイトル】Parkinsons Disease Drug Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5874 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：73 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界のパーキンソン病用薬剤市場規模と予測を収録しています。・世界のパーキンソン病用薬剤市場：売上、2018年-2023年、2024年-2029年 ・世界のパーキンソン病用薬剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のパーキンソン病用薬剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「カルビドパ/レボドパ」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 パーキンソン病用薬剤のグローバル主要企業は、Teva、 Novartis AG、 GSK、 AbbVie、 Merck、 Boehringer Ingelheim、 Impax Laboratories、 Lundbeck、 Sun Pharma、 Wockhardt、 UCB、 Bausch Health、 Acadiaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、パーキンソン病用薬剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のパーキンソン病用薬剤市場：タイプ別、2018年-2023年、2024年-2029年 世界のパーキンソン病用薬剤市場：タイプ別市場シェア、2022年 ・カルビドパ/レボドパ、ドーパミン受容体作動薬、MAO阻害剤 世界のパーキンソン病用薬剤市場：用途別、2018年-2023年、2024年-2029年 世界のパーキンソン病用薬剤市場：用途別市場シェア、2022年 ・病院、診療所、その他 世界のパーキンソン病用薬剤市場：地域・国別、2018年-2023年、2024年-2029年 世界のパーキンソン病用薬剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるパーキンソン病用薬剤のグローバル売上、2018年-2023年 ・主要企業におけるパーキンソン病用薬剤のグローバル売上シェア、2022年 ・主要企業におけるパーキンソン病用薬剤のグローバル販売量、2018年-2023年 ・主要企業におけるパーキンソン病用薬剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Teva、 Novartis AG、 GSK、 AbbVie、 Merck、 Boehringer Ingelheim、 Impax Laboratories、 Lundbeck、 Sun Pharma、 Wockhardt、 UCB、 Bausch Health、 Acadia ************************************************************* ・調査・分析レポートの概要 パーキンソン病用薬剤市場の定義 市場セグメント 世界のパーキンソン病用薬剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のパーキンソン病用薬剤市場規模 世界のパーキンソン病用薬剤市場規模：2022年 VS 2029年 世界のパーキンソン病用薬剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのパーキンソン病用薬剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のパーキンソン病用薬剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：カルビドパ/レボドパ、ドーパミン受容体作動薬、MAO阻害剤 パーキンソン病用薬剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所、その他 パーキンソン病用薬剤の用途別グローバル売上・予測 ・地域別市場分析 地域別パーキンソン病用薬剤市場規模 2022年と2029年 地域別パーキンソン病用薬剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Teva、 Novartis AG、 GSK、 AbbVie、 Merck、 Boehringer Ingelheim、 Impax Laboratories、 Lundbeck、 Sun Pharma、 Wockhardt、 UCB、 Bausch Health、 Acadia ... |
Most people with Parkinson’s disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
This report aims to provide a comprehensive presentation of the global market for Parkinsons Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinsons Disease Drug. This report contains market size and forecasts of Parkinsons Disease Drug in global, including the following market information:
Global Parkinsons Disease Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Parkinsons Disease Drug Market Sales, 2018-2023, 2024-2029, (K Doses)
Global top five Parkinsons Disease Drug companies in 2022 (%)
The global Parkinsons Disease Drug market was valued at US$ 5651 million in 2022 and is projected to reach US$ 7494.1 million by 2029, at a CAGR of 4.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Parkinsons Disease Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Parkinsons Disease Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Doses)
Global Parkinsons Disease Drug Market Segment Percentages, by Type, 2022 (%)
Carbidopa/Levodopa
Dopamine Receptor Agonists
MAO-Inhibitors
Global Parkinsons Disease Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Doses)
Global Parkinsons Disease Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinics
Other
Global Parkinsons Disease Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Doses)
Global Parkinsons Disease Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Parkinsons Disease Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Parkinsons Disease Drug revenues share in global market, 2022 (%)
Key companies Parkinsons Disease Drug sales in global market, 2018-2023 (Estimated), (K Doses)
Key companies Parkinsons Disease Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Teva
Novartis AG
GSK
AbbVie
Merck
Boehringer Ingelheim
Impax Laboratories
Lundbeck
Sun Pharma
Wockhardt
UCB
Bausch Health
Acadia
Outline of Major Chapters:
Chapter 1: Introduces the definition of Parkinsons Disease Drug, market overview.
Chapter 2: Global Parkinsons Disease Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Parkinsons Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Parkinsons Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Parkinsons Disease Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界のパーキンソン病用薬剤市場予測2023-2029：カルビドパ/レボドパ、ドーパミン受容体作動薬、MAO阻害剤] (コード：MMG23JU5874)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界のパーキンソン病用薬剤市場予測2023-2029：カルビドパ/レボドパ、ドーパミン受容体作動薬、MAO阻害剤]についてメールでお問い合わせ |
